Chromosome 13q deletion detected by interphase FISH in multiple myeloma: A study of 100 cases in China

National Medical Journal of China

Volumn 89, Issue 28, 2009, Pages 1979-1982

  Li, Qian ^a   Lu, Yun ^a   Wang, Ya Fei ^a   Liu, Xu Ping ^a   Qi, Jun Yuan ^a   Zou, De Hui ^a   Zhao, Yao Zhong ^a   Qiu, Lu Gui ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

Author keywords

Chromosome 13; Fluoresecence in situ hybridization; Multiple myeloma

Indexed keywords

ADULT; AGED; ARTICLE; CHROMOSOME 13; CHROMOSOME DELETION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS;

ADULT; AGED; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 13; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROGNOSIS;

EID: 84871306802     PISSN: 03762491     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0376-2491.2009.28.012     Document Type: Article

References (13)

1. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol, 2003, 121: 749-757.
2. San Miguel JF, García-Sanz R. Prognostic features of multiple myeloma. Best Pract Res Clin Haematol, 2005, 18: 569-583.
3. Facon T, Aver-Loiseau H, Guillerm G, et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood, 2001, 97: 1566-1571.
4. 2007, 15: 76-78.
5. Fiserova A, Hajek R, Holubova V, et al. Detection of 13q abnormalities in multiple myeloma using immunomagnetically selected plasma cells. Neoplasma, 2002, 49: 300-306.
6. 2007, 28: 223-226.
7. Fonseca R, Harrington D, Oken MM, et al. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma; an eastern cooperative oncology group study. Cancer Res, 2002, 62: 715-720.
8. 2007, 87: 1685-1688.
9. Zojer N, Konigsberg R, Ackermann J, et al. In multiple myeloma, deletion of 13q14 remains an independent adverse prognostic parameter despite its frequent detection by interphase FISH. Blood, 2000, 95: 1925-1930.
10. Kaufmann H, Kromer E, Nosslinger T, et al. Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma. Eur J Haematol, 2003, 71: 179-183.
11. Shaughnessy J Jr, Tian E, Sawyer J, et al. Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II. Br J Haematol, 2003, 120: 44-52.
12. Chiecchio L, Protheroe RK, Ibrahim AH, et al. Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma. Leukemia, 2006, 20: 1610-1617.
13. Avet-Loiseau H, Attal M, Moreau P, et al. Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Mye'lome. Blood, 2007, 109: 3489-3495.